NCT07060001 2026-03-06
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT07177079 2026-02-23
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
University of Iowa
Phase 1 Not yet recruiting
NCT07374029 2026-01-28
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT06297772 2024-06-04
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital
Phase 3 Not yet recruiting